Ocular Therapeutix, Inc.

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

Johnson Fistel, PLLP is investigating whether Ocular Therapeutix, Inc. (NASDAQ: OCUL) or its executive officers complied with the federal securities laws. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

What if I purchased Ocular securities?

This field is for validation purposes and should be left unchanged.

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.

Name(Required)

First Last

Email(Required)

Phone(Required)

Estimated Losses(Required)

Where did you see our press release?(Required)

If you selected 'Other' above, please specify below:(Required)

Would you like to receive future case and securities updates from Johnson Fistel, PLLP via email?(Required)

Yes

Would you like to receive information about Johnson Fistel, PLLP's free portfolio monitoring service?(Required)

Yes

By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, PLLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

I Agree

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.

There is no cost or obligation to you.

Background of the Investigation

On February 17, 2026, Ocular announced topline results from its SOL-1 Phase 3 trial. The company disclosed that 74% of patients maintained vision at nine months, 66% maintained vision at twelve months, and approximately 69% were rescue-free at 52 weeks.

Following this disclosure, Ocular’s stock price declined approximately 27%.

In light of these disclosures, Johnson Fistel is investigating whether Ocular complied with the federal securities laws. If you suffered losses from your investment in Ocular stock, contact Johnson Fistel.